Objective: The aim of this paper was to investigate the acute treatment response and its predictors in a sample of patients with first-episode psychosis admitted to a psychiatric hospital in Iran.
Method: A total of 163 patients with first-episode psychosis were treated with antipsychotics and other medications as prescribed by their treating psychiatrists. Sociodemographic and premorbid data at baseline and clinical data at both baseline and discharge (6±1 weeks after admission) were collected.
Results: Patients showed a response rate of 71.4% for negative symptoms, 91.5% for positive symptoms and 67.5% for functioning. Those having a positive family history and less severe negative symptoms at baseline were less likely to respond in terms of negative symptoms. Higher premorbid and lower baseline functioning as well as acute onset were associated with the treatment response.
Conclusions: Acute treatment response of first-episode psychosis in a clinical sample of a developing country seems to be higher than that of developed countries. However, predictors of response are comparable.
Crespo-FacorroBPelayo-TeranJMPerez-IglesiasR. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research2007; 41: 659–666.
2.
EmsleyROosthuizenPPKiddMKoenLNiehausDJTurnerHJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. Journal of Clinical Psychiatry2006; 67: 1707–1712.
3.
CraigTJSiegelCHopperKLinSSartoriusN. Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. British Journal of Psychiatry1997; 170: 229–233.
4.
Alaghband-RadJBoroumandMAminiH. Non-affective acute remitting psychosis: a preliminary report from Iran. Acta Psychiatrica Scandinavica2006; 113: 96–101.
5.
SartoriusNJablenskyAShapiroR. Two-year follow-up of the patients included in the WHO International Pilot Study of Schizophrenia. Psychological Medicine1977; 7: 529–541.
6.
AminiHAlaghband-RadJOmidA. Diagnostic stability in patients with first-episode psychosis. Australasian Psychiatry2005; 13: 388–392.
7.
JablenskyASartoriusNErnbergG. Schizophrenia: manifestations, incidence and course in different culture. A World Health Organization ten-country study. Psychological Medicine Monograph1992; 20(Suppl.)1–97.
8.
WoodsSW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry2003; 64: 663–667.
9.
SzekeresGKeriSJuhaszA. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American Journal of Medical Genetics B Neuropsychiatric Genetics2004; 124: 1–5.
10.
GoffDCTsaiGLevittJ. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry1999; 56: 21–27.
11.
NormanRMMallaAKCorteseLDiazF. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Research1996; 19: 73–85.
12.
RobinsonDGWoernerMGDelmanHMKaneJM. Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin2005; 31: 705–722.
13.
HopperKWanderlingJ. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. Schizophrenia Bulletin2000; 26: 835–846.
14.
PennDLWaldheterEJPerkinsDOMueserKTLiebermanJA. Psychosocial treatment for first-episode psychosis: a research update. American Journal of Psychiatry2005; 162: 2220–2232.
15.
LehtinenVAaltonenJKoffertTRäkköläinenVSyvälahtiE. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?. European Psychiatry2000; 15: 312–320.
16.
ConusPCottonSAbdel-BakiALambertMBerkMMcGorryPD. Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders2006; 8: 221–231.
17.
RobinsonDGWoernerMGMcMenimanMMendelowitzABilderRM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry2004; 161: 473–479.
18.
HattaKNakamuraHMatsuzakiI. Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients. General Hospital Psychiatry2003; 25: 39–45.
19.
PerkinsDLiebermanJGuH. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry2004; 185: 18–24.
20.
RabinowitzJHarveyPDEerdekensMDavidsonM. Premorbid functioning and treatment response in recent-onset schizophrenia. British Journal of Psychiatry2006; 189: 31–35.
21.
RobinsonDGWoernerMGAlvirJM. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry1999; 156: 544–549.
22.
MojtabaiRSusserESBrometEJ. Clinical characteristics, 4-year course, and DSM-IV classification of patients with nonaffective acute remitting psychosis. American Journal of Psychiatry2003; 160: 2108–15.
23.
SusserEVarmaVKMattooSK. Long-term course of acute brief psychosis in a developing country setting. British Journal of Psychiatry1998; 173: 226–230.
24.
SusserEWanderlingJ. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Sex and sociocultural setting. Archives of General Psychiatry1994; 51: 294–301.
